Inspire Medical Systems Inc
NYSE:INSP

Watchlist Manager
Inspire Medical Systems Inc Logo
Inspire Medical Systems Inc
NYSE:INSP
Watchlist
Price: 136.81 USD -2.3% Market Closed
Market Cap: 4B USD

Inspire Medical Systems Inc
Investor Relations

Inspire Medical Systems Inc. emerged as a beacon of innovation in the medical technology landscape, carving a niche within the realm of obstructive sleep apnea (OSA) treatment. Founded with a vision to redefine the approach to sleep disorders, the company developed a breakthrough solution—a device that stimulates the hypoglossal nerve to maintain an open airway during sleep. This technology, known as Inspire therapy, represents a significant departure from traditional treatments like the cumbersome and often uncomfortable Continuous Positive Airway Pressure (CPAP) machines. By addressing the root cause of airway obstruction, Inspire provides an effective, less intrusive alternative, enhancing the overall quality of life for patients who struggle with conventional methods.

Inspire Medical Systems makes money by marketing its implantable device primarily through a network of sleep centers and hospitals. The company operates in a business model that combines device sales with a supportive service infrastructure, ensuring that both healthcare providers and patients are well-acquainted with its innovative therapy. The revenue stream is fueled not only by the initial sales of the device but also through ongoing follow-ups and software updates necessary for optimal device functionality. By positioning itself at the intersection of customer care and cutting-edge technology, Inspire captures significant value in the growing OSA market, all while reinforcing its reputation as a leader in innovative medical solutions.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 3, 2025
AI Summary
Q3 2025

Revenue Growth: Inspire reported Q3 revenue of $224.5 million, up 10% year-over-year and reaffirmed full-year revenue guidance of $900–910 million (12–13% growth).

EPS Guidance Raised: The company increased its full-year 2025 EPS guidance to $0.90–$1 per share, up from $0.40–$0.50, citing strong operational performance.

Inspire V Transition: Over 75% of centers have transitioned to the Inspire V system, with nearly all top implanting centers now using it; the transition is expected to be mostly complete by year-end.

Marketing & Operating Leverage: Increased investment in direct-to-consumer marketing is driving strong patient flow, while expense discipline and territory consolidation are boosting operating margins.

Reimbursement Tailwinds: CMS finalized an 11% increase in 2026 physician fee schedule and proposed increased hospital reimbursement for Inspire procedures, expected to support future growth.

2026 Early Outlook: Management indicated early expectations for 10–11% revenue growth in 2026, citing some headwinds but strong momentum with Inspire V, with formal guidance to be provided in January.

GLP-1 Impact: Survey data indicates GLP-1 drugs are increasing patient inflow to sleep centers, which is seen as a net positive for Inspire as many new candidates become eligible for therapy.

Key Financials
Revenue
$224.5 million
U.S. Revenue
$214.4 million
Revenue Outside the U.S.
$10.1 million
Gross Margin
85.8%
Operating Expenses
$183.1 million
Operating Income
$9.6 million
Net Income
$9.9 million
Earnings Per Share
$0.34
Adjusted EBITDA
$44 million
Adjusted EBITDA Margin
20%
Adjusted Net Income Per Share
$0.38
Operating Cash Flow
$68.5 million for Q3; $64.5 million year-to-date
Cash and Investments
$411 million
Share Repurchases
$50 million in Q3; $125 million year-to-date
Diluted Shares Outstanding
29.6 million (Q3); ~30 million (full year expected)
Tax Rate
25% (expected for 2025)
Earnings Call Recording
Other Earnings Calls

Management

Mr. Timothy P. Herbert
Founder, Chairman, CEO & President
No Bio Available
Mr. Richard J. Buchholz
Chief Financial Officer
No Bio Available
Mr. Randall A. Ban
Chief Commercial Officer
No Bio Available
Dr. Charisse Y. Sparks FAAOS, M.D.
Chief Medical Officer
No Bio Available
Mr. Carlton W. Weatherby
Chief Strategy Officer
No Bio Available
Mr. John C. Rondoni
Chief Technology Officer
No Bio Available
Ms. Ezgi Yagci
Vice President of Investor Relations
No Bio Available
Mr. Bryan K. Phillips J.D.
Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
No Bio Available
Ms. Melissa J. Mann
Chief People Officer
No Bio Available
Mr. Ivan Lubogo
Senior Vice President of U.S. Sales
No Bio Available

Contacts

Address
MINNESOTA
Golden Valley
5500 Wayzata Blvd Ste 1600
Contacts
+17639575037.0
www.inspiresleep.com